A US sponsor planning a first-in-human study reasons from one federal clock. Under 21 C.F.R. § 312.40(b)(1) the trial may begin thirty days after the FDA receives the IND unless the agency imposes a clinical hold, and the count starts at receipt. The institutional review board runs on a separate, site-level track that the sponsor manages rather than the regulator.121 C.F.R. § 312.40(b)(1) (IND effective 30 days after receipt absent a clinical hold); 45 C.F.R. § 46.114(b) (single IRB for cooperative research). Europe replaced that arithmetic in 2022 with a single portal, a two-part assessment and a set of statutory clocks that start at validation, not at receipt, and that the Member States may shorten but not lengthen. On top of those clocks three of the four Nordic medicines agencies have, since the summer of 2025, each placed a national promise, measured in days, fourteen in Denmark, thirty in Sweden and thirty in Finland, and Norway has taken a seat at the European pilot instead. The numbers invite comparison. They are not comparable, because none of the four counts from the same moment, none of them is written in a statute, and each is conditional on a trial design that the promise itself constrains.
1. Fourteen Days from What: Four Nordic Clocks That Start at Different Points
Denmark's number has a political pedigree. The government's strategy for life science towards 2030, published in November 2024, commits to establishing a fourth medical research ethics committee "so that phase 1 trials can be processed in 14 days", and measures the country against a single indicator, the number of clinical trials per million inhabitants, on which Denmark stood at 31 in 2023, the highest figure in the strategy's own comparison of the EU14 countries, the United Kingdom and Switzerland.2Danish Government, 'Strategy for life science towards 2030' (November 2024), benchmark 2, initiatives 2.1, 2.2 and 2.4. The commitment became an administrative procedure on 7 August 2025, when the Danish Medicines Agency (DKMA) and the medical research ethics committees (VMK) published a joint guidance, version 1.0, on expedited assessment of phase I and integrated phase I-II applications, applied from 14 August 2025.3DKMA and VMK, 'Expedited Assessment of Applications for Phase I and Integrated Phase I-II Clinical Trials with Medicinal Products' (Version 1.0, 7 August 2025). What the guidance promises is precise and narrower than the headline. Validation takes seven days from submission, and a validation request for information (RFI) adds five days for the sponsor and five for the authorities. The day the application is declared valid is T0, and fourteen days after T0 the sponsor receives either an approval of both Parts or an RFI. An RFI opens a twelve-day response window and a ten-day review, so the second decision point is day 36. A second RFI, with five days each way, makes the third day 46. Counted from submission rather than from T0, the promise is a decision between day 21 and day 63, and the guidance says of itself that the procedure "will be continuously refined".3
The conditions are as material as the days. Only phase I and integrated phase I-II trials qualify, master protocols only where no more than one investigational product lacks a marketing authorization, and the application must contain both Part I and Part II. The core procedure is for trials conducted in Denmark alone. A multinational application may be expedited only by prior agreement with the DKMA and the VMK, and only if the sponsor has itself secured agreements from every other Member State involved to keep the same timelines for both Parts. The procedure cannot be combined with a coordinated study under the CTR and the IVDR. It is suspended during the winter clock stop of the Clinical Trials Information System (CTIS) and, by a Danish addition, during weeks 29 to 31 of the summer. And the fifty-day extension that Art. 6(7) CTR allows for advanced-therapy products is, "as a general rule, not applied in Denmark", which is an administrative choice, not a statutory one, and is worded as such.3 For everything outside the expedited track the DKMA's published target for a valid mononational application is an assessment on day 26 and a decision on day 31, with early-phase trials prioritized.4DKMA, 'How to apply for clinical trials with medicinal products in Denmark and Europe' (webpage): day 26 assessment, day 31 decision for valid mononational trials.
Against that stands the Regulation's own arithmetic, which no national promise can alter. Art. 5(3) CTR gives the reporting Member State ten days from submission to validate. Art. 6(4) CTR gives it 45 days from the validation date to deliver the final Part I report, which for a multinational trial Art. 6(5) CTR divides into an initial assessment of 26 days, a coordinated review of twelve and a consolidation of seven. Art. 6(8) CTR lets one request for information extend the 45 days by up to 31, and Art. 7(2) and (3) CTR run the same 45 and 31 for each Member State's Part II. Art. 8(1) CTR requires the single decision within five days of the later of the two conclusions.5Regulation (EU) No 536/2014 (CTR), Art. 4, Art. 5(3), Art. 6(4), (5), (7) and (8), Art. 7, Art. 8, Art. 14, Art. 74, Art. 76. The Commission's own count of that sequence is 75 days from submission to decision without a request for information and 106 with one.6European Commission, Proposal for a European Biotech Act, COM(2025) 1022 final (16 December 2025), explanatory memorandum on the amendments to the CTR. The Union-wide median, measured across every decision issued in the first quarter of 2026, was 118 days.7ACT EU, 'Monitoring the European clinical trials environment, January-March 2026': median 118 days; per-country application counts since 31 January 2022. The same monitoring report records what Denmark has made of the system since CTIS opened on 31 January 2022. It counts 961 initial applications naming Denmark, 328 of them mononational, and Denmark acting as reporting Member State 216 times, against 640 applications for Sweden, 345 for Norway, 296 for Finland and 15 for Iceland, in a country of six million people.7
Sweden's promise starts from a different point. Since 1 September 2025, Läkemedelsverket has run a fast track for mononational applications under which an application is assessed within 26 days from the day it is valid and, if no supplementary information is needed, approved within 30 days after it has been submitted in CTIS. The two sentences use two clocks, one from validation and one from submission. The scheme applies to all mononational applications with a chemical investigational medicinal product, a restriction that leaves every biologic on the ordinary timeline.8Läkemedelsverket, 'Snabbspår för mononationella ansökningar om klinisk läkemedelsprövning' (18 June 2025): from 1 September 2025; chemical IMPs only. The agency's own statistics for 2023, the last year it had published at the time of writing, put the average processing time for the 35 mononational applications that received a positive decision at 80.3 days, within a range of 55 to 155, with seven of them lengthened by the seventeen days of the winter clock stop.9Läkemedelsverket, 'Statistik för kliniska prövningar av läkemedel och medicintekniska produkter 2023' (20 May 2024): 52 mononational applications; average 80.3 days. Finland moved third and chose the third possible clock. From 11 February 2026, Fimea and the National Committee on Medical Research Ethics (Tukija) may issue a decision on a Finland-only application within 30 calendar days of its submission to CTIS, if no request for information is needed, for every phase and every sponsor. The head of Fimea's clinical-trials sector described the design choice herself, saying that the calculation of deadlines "already begins when the application is received in the portal", which "differs from the practices of many other countries".10Fimea, 'Fimea and Tukija to speed up evaluation of national clinical trials' (11 February 2026). Norway has no national track at all. The CTR applies there through the EEA Agreement, given effect in Norwegian law by an implementing regulation in force from 4 February 2022, four days after CTIS opened, with the Norwegian Medical Products Agency (DMP) and the ethics committee REK KULMU issuing the decision jointly. Norway's contribution to the race is the national action plan for clinical studies and clinical research 2026 to 2036, presented on 23 March 2026, whose targets include a place among the top three countries in Europe for clinical trials per million inhabitants and, on approvals, participation in the European pilot rather than a Norwegian clock.11Regjeringen, press release of 23 March 2026 on the Nasjonal handlingsplan for kliniske studier og klinisk forskning 2026-2036; DMP, 'Klinisk utprøving av legemidler til mennesker'. Iceland applies the Regulation through its Regulation No 1311/2021 and has seen fifteen applications in four years.12Reglugerð nr. 1311/2021 um klínískar prófanir á mannalyfjum (23 November 2021), in force 31 January 2022.
So a sponsor reading four brochures reads four different quantities. Denmark's fourteen days run from validation and end in either an approval or a question. Sweden's 26 run from validation and its 30 from submission, for small molecules only. Finland's 30 run from submission and do not stop for validation queries. Norway's days are the Regulation's. All four count calendar days that roll to the next business day over weekends and holidays, all four pause for the winter clock stop, and Denmark's pauses again from mid-July.
Four Nordic regulators advertise speed in days, and no two of them start counting from the same moment. The figure a sponsor compares is not the figure the sponsor will live.
None of this makes the promises empty. Denmark in particular has built the committee capacity and the joint working method between agency and ethics committee that a fourteen-day turnaround requires, and the application counts in the monitoring report show sponsors responding. It makes the promises non-fungible. A site-selection model that enters fourteen for Denmark, thirty for Sweden and thirty for Finland in one column has already made a category error, and a financing plan built on that column inherits it.
2. Mononational by Design: What the Speed Costs When a Second Country Joins
Every one of the three national tracks is a mononational track. Denmark's expedited procedure applies to trials conducted in Denmark, Sweden's to trials planned exclusively in Sweden, and Finland's to applications evaluated only in Finland.3810 The speed is therefore bought with a design decision made before submission. At the moment of authorization the trial must name one country. For a first-in-human study in a specialized phase I unit that is often the natural design. For an integrated phase I-II protocol, which Denmark's track expressly admits, it is a constraint that binds later, when the expansion cohort needs patients a country of six million cannot supply on the protocol's timeline, and the sponsor has to add a Member State to a trial that was authorized fast precisely because it had none to add.
The Regulation offers two doors and neither is quick. Under Art. 14 CTR the sponsor may extend an authorized trial to an additional Member State only after the initial decision has been notified, and the original reporting Member State stays reporting Member State. The additional State then has, under the same article, 52 days from submission to decide, which one request for information extends by up to 31, with a twelve-day response window, a twelve-day coordinated review and a seven-day consolidation folded inside.5 Or the sponsor gives up the mononational advantage from the start and applies multinationally, on the 26, twelve and seven days of Art. 6(5) CTR. Denmark's guidance does provide an expedited multinational variant, with the reporting Member State sharing its assessment on day 14, the other States responding by day 21 and decision points at days 21, 48 and 58, but only where the sponsor has itself obtained, before submission, the agreement of every other Member State concerned to those timelines for both Parts.3 The DKMA cannot bind Läkemedelsverket or Fimea to its calendar. The sponsor is invited to try. The sequencing question that Insight 25 raised for Austria's 35-day mononational pathway, when to convert and what the conversion costs, therefore returns in the Nordics with a sharper edge, because the Nordic tracks are faster and the countries smaller.
Scope restrictions do the same work less visibly. A US biotech whose lead asset is an antibody or a cell product finds that Sweden's track is closed to it by the words "chemical investigational medicinal product", and that Denmark's willingness to forgo the advanced-therapy extension of Art. 6(7) CTR is a stated practice with a stated reservation. Neither restriction appears in the day counts that circulate.
The baseline against which all of this is measured is itself in motion. On 16 December 2025 the Commission proposed the European Biotech Act, a regulation that rewrites the CTR's authorization chapter (Art. 58 Biotech Act). The proposed Art. 5b CTR would have the reporting Member State validate within seven days of submission. The proposed Art. 6(4) CTR would require the final Part I report within 42 days from the submission date, no longer from validation, with the multinational phases compressed to 28, seven and seven days and a request for information extending the period by at most 28 days against a sponsor response window of fourteen. The proposed Art. 7(2) CTR would give each Member State the same 42 days from submission for Part II, and Art. 8(1) CTR would keep the five-day decision. The fifty-day advanced-therapy extension is not carried into the new Art. 6 CTR at all. The Commission's explanatory memorandum states the result as 106 days falling to 75 with a request for information and 75 falling to 47 without one, with the reporting Member State's assessment, including its ethics committee's review, to serve as the reference the others rely on.13COM(2025) 1022 (n 6), Art. 58, points (4) to (7): proposed Art. 5b, 6, 7 and 8 CTR. If that text passes, Finland's from-submission design becomes the Union's, Sweden's mixed clock becomes an anomaly, and Denmark's fourteen days from validation lose their comparator, because the Regulation would no longer have a validation-based clock to be faster than. As of publication the proposal was pending. The rapporteurs of the European Parliament's SANT and ITRE committees presented their draft report in June 2026 proposing further reductions and dedicated fast tracks for rare diseases and advanced therapies. The deadline for amendments fell on 7 July 2026, the committee vote was not scheduled before December 2026, and the Council had adopted no position.14Procedure 2025/0406(COD); SANT and ITRE joint draft report PE789.987 of June 2026; amendments deadline 7 July 2026; committee vote scheduled December 2026. A sponsor choosing a Nordic site in 2026 for a program that files in 2027 is choosing against a rulebook that may be rewritten between the two dates.
3. The Committee Is the Constraint: Ethics Review as the Binding Variable
The Regulation harmonized the clocks and left the ethics committees to the Member States. Art. 4 CTR requires an ethics review performed by an ethics committee in accordance with national law, on timelines the Member State must keep compatible with the Regulation's. Art. 8(4) CTR obliges a Member State to refuse authorization where an ethics committee has issued a negative opinion that under that State's law is valid for the entire State.5 What that means in practice differs in each of the four countries, and it is the difference that decides whether a fast track can exist.
Denmark wrote the committee into the decision. Under § 10 of the Danish Act on Clinical Trials of Medicinal Products (lov om kliniske forsøg med lægemidler) the DKMA and the medical research ethics committees coordinate their handling of an application, and under § 11(1) the DKMA issues the decision. Under § 11(4) and (5) the DKMA assesses the health-scientific aspects of Part I while the committee assesses the ethical aspects of Part I and the whole of Part II. Under § 11(6) the DKMA cannot approve a clinical trial, or approve it subject to conditions, if the committee disagrees with the reporting Member State's Part I conclusion on any of the grounds in Art. 8(2) CTR or finds, on duly justified grounds, that Part II is not complied with.15Lov om kliniske forsøg med lægemidler, LBK nr 1252 af 31/10/2018, §§ 10 and 11. The committees themselves are national bodies. The committee act places clinical trials of medicinal products before the medical research ethics committees rather than the regional ones, and the act on the ethical review of clinical investigations of medical devices, under which the committees have been established since 2022, composes each committee of eight members, a chair active in health research, five members nominated through the regional councils, and two nominated by patient organizations.16Komitéloven, LBK nr 1268 af 28/11/2024, § 1, stk. 2, and § 15, stk. 6; Lov nr 1853 af 9. december 2020, §§ 3 and 4. Denmark's fourteen days are possible because a national committee sits inside the same procedure as the agency and a fourth such committee was promised to absorb the phase I load. The number is in no statute. The committee is.
The statute that was meant to follow did not arrive. On 26 February 2026 the Minister for the Interior and Health introduced bill L 132, amending the committee act, the trials act and the medical-device trials act to introduce risk-based assessment, under which lower-risk projects could be decided by a sub-committee, the chair or the secretariat, to add a ninth, interdisciplinary member to each medical committee, and to widen the information given to trial participants, with entry into force planned for 1 July 2026. The general election was called the same day, the bill lapsed, unenacted, with the election of 24 March 2026, and the government formed on 3 June 2026 had not reintroduced it as of publication.17Folketinget, L 132 (2025-26), introduced 26 February 2026, lapsed (bortfaldet) with the election of 24 March 2026; government formed 3 June 2026. A sponsor told that Denmark is moving to risk-based ethics review is being told about a bill that no longer exists. The administrative fast track stands on its own, on the fourth committee and a guidance that promises to keep refining itself.
Sweden shows what the alternative structure costs. The ethics review is performed by the Swedish Ethical Review Authority (EPM), which delivers an opinion to Läkemedelsverket, and Läkemedelsverket issues the decision.18Lag (2018:1091) med kompletterande bestämmelser om etisk granskning till EU:s förordning om kliniska prövningar av humanläkemedel, §§ 2 and 3. In its response of 7 April 2026 to the Biotech Act proposal the EPM described its own machinery in terms no sponsor's feasibility questionnaire would elicit. Its response describes roughly 500 part-time members sitting in divisions of sixteen, meeting monthly to decide around twenty cases a session, with two weeks' access to the documents beforehand. The authority receives applications only after the agency's validation, has no CTIS access of its own, returns its opinion through the agency, which normally has three to five calendar days at its disposal for the hand-over, and waits for the input of regional biobank centers. And it concludes that some of the proposed periods are not feasible at all and that the others are achievable only with more money, more committees, legislative change and direct portal access.19Etikprövningsmyndigheten, remissvar to Socialdepartementet on COM(2025) 1022, dnr 2026-00876-03 (7 April 2026). The government's response, announced on 26 May 2026 as part of the spring amending budget for 2026 submitted to the Riksdag on 13 April, was SEK 6 million for the authority to shorten its processing times, framed expressly against the Biotech Act's forthcoming timelines and the national life science strategy's aim of attracting high-quality research investment.20Regeringen, 'Regeringen satsar 6 miljoner kronor för kortare handläggningstider för kliniska prövningar' (26 May 2026). The 30-day Swedish promise is an agency promise made on top of that committee. The agency's own 2023 average of 80 days for mononational trials is the number that includes it.9
Finland and Norway sit between the two. Finland's Clinical Trials Act placed the ethics review with a single national committee, Tukija, whose negative opinion binds Fimea, and Fimea issues the decision within five days of the two conclusions. A single national committee is why Finland could promise 30 days from submission for every phase.21Laki kliinisestä lääketutkimuksesta (983/2021), in force 31 January 2022; Fimea, 'Trial application and modifications' (webpage). In Norway REK KULMU, the committee created within the regional ethics system for trials of medicinal products and medical devices, assesses Part II alone and Part I together with the DMP, and the two issue the decision jointly.11 For a US sponsor whose model of ethics review is the single-IRB reliance of 45 C.F.R. § 46.114(b), the point is structural. In Denmark the committee co-decides, in Sweden it advises through an agency that holds the portal, in Finland it can veto, and in none of the four can the sponsor choose its reviewer.1
4. Outside the Regulatory Clock: Representatives, Insurance, Data and the EEA Lag
The first thing the clock does not cover is the sponsor's own standing. Art. 74(1) CTR requires a sponsor not established in the Union to have a legal representative established there, responsible for the sponsor's compliance and the addressee of every communication under the Regulation. Art. 74(2) and (3) CTR let a Member State accept a contact person instead, for trials on its own territory or, by joint choice, for multinational ones.5 Denmark has not taken that option. The DKMA's guidance to sponsors states that a sponsor residing outside the EU must register a legal representative residing in the EU in CTIS, and that it is not sufficient for the Union contact point to reside there.22DKMA, 'Clinical trials: questions and answers' (webpage): legal representative residing in the EU required for sponsors outside the EU; contact point not sufficient. Whether one representative in one Nordic country serves a trial that later adds another depends on each State's election under Art. 74 CTR, which is national law and does not appear in the portal. A US sponsor that has never appointed such a representative discovers at validation that it needs one, and the seven-day Danish validation window is not designed for that discovery.
The second is Part II itself, which the Regulation leaves national by construction. Art. 7(1) CTR hands each Member State the informed-consent documents, the arrangements for compensating subjects and investigators, recruitment, data protection, the suitability of investigators and sites, damage compensation under Art. 76 CTR and the rules on biological samples. The four countries answer differently on the item a US sponsor budgets last. Denmark does not require a stand-alone insurance policy where the trial sites are covered by the public patient-compensation scheme, and the committees' own guidance makes the sponsor responsible for coverage at every Danish site, which for a private phase I unit means a policy after all. Sweden requires sponsor insurance and accepts the insurer's English documentation as an annex, and Finland requires an official certificate of insurance or an equivalent guarantee. Norway requires a certificate from the Norwegian Drug Liability Association, the Legemiddelansvarsforeningen.23European Commission and MedEthicsEU, 'Overview of Part II requirements in a clinical trial application per Member State'; VMK, questions and answers on the CTR and CTIS. Subject information must be in Danish, with a validated translation and an interpreter where the participant does not read it, and in Sweden the documents for participants must be in Swedish.23 None of these items runs on the agency's clock, and each of them is a ground for a Part II request for information that stops it.
The third is data, and here Denmark's advantage and Denmark's rules are the same thing. The registries that make Danish sites attractive sit behind § 46 of the Danish Health Act (sundhedsloven), under which patient-record data may be disclosed to a researcher for a specific project where the project has been approved under the committee act, the device-trials act or the trials act or, outside those acts, with the approval of the regional council, which has 35 days to decide. An amending act of June 2025 added a single point of contact for the secondary use of health data, and the strategy holds out a national analytics platform to be developed towards 2027.24Sundhedsloven, § 46; Lov nr 717 af 20/06/2025 (single point of contact for secondary use of health data); strategy (n 2), initiative 2.4. The trial's own data are governed by the GDPR, with the sponsor as controller wherever it is established and the health data as special-category data, the regime Insight 03 examines. The secondary-use architecture that will eventually federate the Nordic registries is the subject of Insight 54. The point here is narrower. The research-data approvals that make a Danish trial worth running are granted by bodies the DKMA's fourteen days do not touch.
The fourth is that the Nordics are not one regulatory space. Denmark, Sweden and Finland are Member States. Norway and Iceland apply the CTR through the EEA Agreement, which incorporated the Regulation in 2015, well ahead of its application date, but incorporates each amendment separately, by decision of the EEA Joint Committee, after the Union has adopted it.12 The Biotech Act's rewritten clocks will therefore arrive in Copenhagen, Stockholm and Helsinki before they arrive in Oslo and Reykjavik, and the lag for cybersecurity legislation, examined in Insight 26, is a caution against assuming it will be short. The one Nordic-wide instrument that exists at publication is the FAST-EU pilot, launched on 30 January 2026 under the Clinical Trials Coordination Group of the Heads of Medicines Agencies with MedEthicsEU, which offers selected multinational trials a decision within ten weeks of submission. Denmark, Sweden, Finland and Norway all participate, Denmark keeps its own phase I track running beside it, and the pilot is voluntary, capped monthly and planned for one year.25DKMA, news of 23 January 2026 on the FAST-EU pilot from 30 January 2026; DMP, 'FAST-EU' (webpage): 70 calendar days, one-year voluntary pilot, monthly caps. The Nordic Trial Alliance that once coordinated the region's trial infrastructure closed in 2023. What remains is one national support organization per country, Trial Nation in Denmark, NorTrials in Norway, Kliniska Studier Sverige in Sweden and, launched on 9 June 2026 after a government decision at its mid-term policy review, FinTrials in Finland, each of which finds sites in its own country.26NordForsk, 'Nordic Trial Alliance' (project 2013 to 2023); Trial Nation (Denmark, 2018); Finnish Government, press release of 9 June 2026 on FinTrials.
5. Strategic Considerations
The questions a Nordic site-selection decision turns on are not the ones a fast track answers. Which Member State should be reporting Member State determines whose ethics committee's review the others will rely on if the Biotech Act passes in its proposed form, and that choice is made at first submission and, under Art. 14 CTR, cannot later be changed. Whether the lead asset is a chemical or a biological product decides whether Sweden's track exists for it. Whether the protocol is a phase I or an integrated phase I-II design decides whether Denmark's does, and an integrated design carries the second-country problem inside it from day one. Whether the dossier will survive a day-14 assessment without a request for information depends on the quality of the chemistry, manufacturing and non-clinical package as the assessors, not the sponsor, judge it, and the guidance makes the whole promise conditional on exactly that.
Behind those sit questions only the sponsor can answer. What the financing plan assumes about first-patient-in, and whether it assumed day 14 from validation or day 14 from submission. Whether the group has an EU legal representative and what its mandate says about a trial that adds a country. What the site agreement with the region that owns the hospital, the pharmacy set-up and the investigator's calendar will take, none of which the DKMA governs. And whether a program that files in 2026 on today's clocks will be amended in 2027 on tomorrow's, with an ethics committee in one country that has said publicly it cannot meet the proposed timelines without changes that had not been made.
For a US-listed sponsor the feedback loop is concrete. A first-in-human start that slips from a fourteen-day plan to a fifty-three-day reality is a milestone missed against a disclosed timeline, and a trial that has to add a country under Art. 14 CTR is a protocol amendment with a disclosure question attached. Whether any of that happens depends on the design of the trial, the composition of the group and the countries chosen, and it requires analysis tailored to the program, the product and the commercial context.